CALR

Summary

CALR (calreticulin, HGNC:1455) is a protein-coding gene on chromosome 19p13.13, encoding Calreticulin (P27797). Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. In precision oncology, CALR EXON 9 FRAMESHIFT confers sensitivity to Peginterferon Alfa-2a in Essential Thrombocythemia (CIViC Level B).

Calreticulin is a highly conserved chaperone protein which resides primarily in the endoplasmic reticulum, and is involved in a variety of cellular processes, among them, cell adhesion. Additionally, it functions in protein folding quality control and calcium homeostasis. Calreticulin is also found in the nucleus, suggesting that it may have a role in transcription regulation. Systemic lupus erythematosus is associated with increased autoantibody titers against calreticulin. Recurrent mutations in calreticulin have been linked to various neoplasms, including the myeloproliferative type.

Source: NCBI Gene 811 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 96 total — 1 pathogenic
• Phenotypes (HPO): 84
• Druggable target: yes
• Precision-oncology evidence (CIViC): 1 curated variant–drug association
• MANE Select transcript: NM_004343

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1455
Approved symbol	CALR
Name	calreticulin
Location	19p13.13
Locus type	gene with protein product
Status	Approved
Aliases	RO, SSA, cC1qR, CRT, FLJ26680, CALR1
Ensembl gene	ENSG00000179218
Ensembl biotype	protein_coding
OMIM	109091
Entrez	811

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 12 protein_coding, 3 retained_intron, 2 nonsense_mediated_decay

ENST00000316448, ENST00000586760, ENST00000586803, ENST00000586967, ENST00000587486, ENST00000588454, ENST00000590325, ENST00000680816, ENST00000861560, ENST00000929786, ENST00000929787, ENST00000929788, ENST00000929789, ENST00000929790, ENST00000929791, ENST00000929792, ENST00000957023

RefSeq mRNA: 1 — MANE Select: NM_004343 NM_004343

CCDS: CCDS12288

Canonical transcript exons

ENST00000316448 — 9 exons

Exon	Start	End
ENSE00001255537	12943537	12943629
ENSE00001255547	12940744	12940887
ENSE00001255558	12940541	12940654
ENSE00001255567	12940243	12940452
ENSE00001255601	12943713	12944489
ENSE00001255609	12938609	12938770
ENSE00003557148	12940053	12940147
ENSE00003643363	12939428	12939631
ENSE00003684797	12939134	12939235

Expression profiles

Bgee: expression breadth ubiquitous, 289 present calls, max score 99.80.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 1492.0951 / max 9312.6897, expressed in 1828 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
174039	1484.3111	1828
174049	4.3498	1484
174042	3.0667	1492
174050	0.3675	135

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	99.80	gold quality
left lobe of thyroid gland	UBERON:0001120	99.64	gold quality
right lobe of thyroid gland	UBERON:0001119	99.62	gold quality
thyroid gland	UBERON:0002046	99.56	gold quality
islet of Langerhans	UBERON:0000006	99.52	gold quality
smooth muscle tissue	UBERON:0001135	99.44	gold quality
adenohypophysis	UBERON:0002196	99.42	gold quality
colonic epithelium	UBERON:0000397	99.34	gold quality
rectum	UBERON:0001052	99.33	gold quality
upper lobe of left lung	UBERON:0008952	99.29	gold quality
mucosa of transverse colon	UBERON:0004991	99.25	gold quality
right lobe of liver	UBERON:0001114	99.24	gold quality
granulocyte	CL:0000094	99.20	gold quality
ascending aorta	UBERON:0001496	99.20	gold quality
thoracic aorta	UBERON:0001515	99.18	gold quality
left uterine tube	UBERON:0001303	99.17	gold quality
right ovary	UBERON:0002118	99.16	gold quality
left ovary	UBERON:0002119	99.16	gold quality
body of pancreas	UBERON:0001150	99.14	gold quality
ventricular zone	UBERON:0003053	99.14	gold quality
right coronary artery	UBERON:0001625	99.13	gold quality
minor salivary gland	UBERON:0001830	99.13	gold quality
adrenal tissue	UBERON:0018303	99.13	gold quality
metanephros cortex	UBERON:0010533	99.12	gold quality
gall bladder	UBERON:0002110	99.11	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	99.10	gold quality
left adrenal gland cortex	UBERON:0035825	99.10	gold quality
endocervix	UBERON:0000458	99.08	gold quality
left adrenal gland	UBERON:0001234	99.08	gold quality
body of uterus	UBERON:0009853	99.06	gold quality

Single-cell (SCXA)

Detected in 19 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-MTAB-9154	yes	3160.57
E-HCAD-24	yes	2575.79
E-MTAB-10042	yes	1950.88
E-MTAB-9067	yes	1928.56
E-MTAB-9801	yes	1479.82
E-HCAD-6	yes	1111.64
E-MTAB-9467	yes	48.32
E-CURD-112	yes	35.09
E-CURD-46	yes	30.86
E-CURD-122	yes	23.09
E-HCAD-9	yes	20.07
E-GEOD-135922	yes	10.29
E-HCAD-13	no	2759.32
E-GEOD-76312	no	1494.60
E-CURD-7	no	1438.18

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR, ATF6, E2F1, E2F4, ESR1, GATA3, GATA6, MECOM, MEF2C, NKX2-5, NR2F1, PPARA, PPARD, PPARG, TCF3, TFAP2A, TTF1, YY1

miRNA regulators (miRDB)

53 targeting CALR, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-3136-3P	99.57	66.59	781
HSA-MIR-7155-3P	99.57	66.48	794
HSA-MIR-2116-5P	99.32	69.34	1273
HSA-MIR-4721	99.26	66.05	818

Literature-anchored findings (GeneRIF, showing 40)

• location was observed on or near the cell surface suggesting it might participate in surface membrane transport of iron (PMID:11891802)
• Regulation of expression during induction of differentiation in human myeloid cells; evidence for remodeling of the endoplasmic reticulum (PMID:12065601)
• Anti-adhesive activity of thrombospondin is mediated by the N-terminal domain of the cell surface protein (PMID:12147682)
• role in class I loading process (PMID:12235131)
• Data show that CD1d associates in the ER with both calnexin and calreticulin and with the thiol oxidoreductase ERp57 in a manner dependent on glucose trimming of its N-linked glycans. (PMID:12239218)
• Calreticulin interacts with C/EBPalpha and C/EBPbeta mRNAs and represses translation of C/EBP proteins. (PMID:12242300)
• role in calcium homeostasis and apoptosis (PMID:12324449)
• Physical and functional interaction between cell-surface calreticulin and the collagen receptors integrin alpha2beta1 and glycoprotein VI in human platelets (PMID:12362238)
• Maturation-dependent expression of this protein in monocyte-derived dendritic cells. (PMID:12538033)
• Dengue 4 virus minus strand 3’UTR RNA binds with calreticulin in human monocytes (PMID:12584332)
• CD59 is an adaptor for ecto-calreticulin in neutrophils (PMID:12646570)
• identification as a nuclear matrix protein associated with human colon cancer (PMID:12704787)
• disease specific antigenic epitopes on CRT molecule, predominantly recognised by IgA Ab of patients suffering from a particular disease (PMID:14624761)
• calreticulin is expressed in melanoma cells of primary as well as of metastatic lesions and may not have the same causative role as calnexin in melanoma metastasis (PMID:14732231)
• the contribution of both the b and b’ domains of ER-60 to the binding with calnexin and calreticulin was revealed (PMID:15236594)
• the lectin site of CRT is the main target for gentamicin binding (PMID:15351734)
• A polypeptide binding conformation of CALR is induced by deletion of the C-terminal acidic region. (PMID:15383281)
• conclude that calreticulin promotes the folding of human leukocyte antigen class I molecules to a state in which, at low temperature, they spontaneously acquire peptide binding capacity (PMID:15494401)
• Up-regulation of calreticulin is associated with bladder cancer (PMID:15596044)
• The thrombospondin-1 (TSP-1) binding site in calreticulin, spanning residues 19-36, augments the expression of TSP-1 and is a potent triggering factor for T cell migration. (PMID:15634883)
• modulation of CEBPA by calreticulin represents a novel mechanism involved in the differentiation block in CBFB-SMMHC AML. (PMID:15855281)
• Our study has identified, by immunoprecipitation and direct protein sequencing (LC/MS/MS), binding of CD69 to an N-terminal protein fragment of calreticulin expressed on the cell surface of human PBMCs. (PMID:15893733)
• C1q functions as a chemotactic factor for immature dendritic cells, and migration is mediated through ligation of both gC1qR and cC1qR/CR. (PMID:16140380)
• single C-terminal alpha-helix was of major importance to the conformational stability of calreticulin (PMID:16522185)
• CRT in the post-endoplasmic reticulum compartments may act as a negative regulator of the cell surface CFTR (PMID:16527813)
• These results indicate that the calcium- and zinc-responsive regions of calreticulin reside strictly in the N-/C-domain. (PMID:16542777)
• Novel mechanism by which calareticulin is involved in the regulation of radiosensitivity and radiation-induced apoptosis in malignant glioma cells. (PMID:16951181)
• Calreticulin/NY-ESO-1 interactions provide a direct link between NY-ESO-1, the innate immune system and, potentially, the adaptive immune response against NY-ESO-1. (PMID:16951317)
• CRT is located on the surface of metaphase chromosomes (PMID:16974078)
• Phospholamban in the human esophagus might be of less importance for regulation of SERCA than in heart. Lower expression of calsequestrin and calreticulin might contribute to increased lower esophageal sphincter pressure in achalasia. (PMID:17009399)
• These results show that Calreticulin is likely to play a pivotal role in the differentiation of human colonic adenocarcinomas. (PMID:17390051)
• calreticulin has a peptide-binding specificity for hydrophobic sequences (PMID:17499031)
• CALR and Hsp90 stabilize INSR. (PMID:17563366)
• Two novel mutations in the CALR gene were identified. (PMID:17655857)
• cell surface calreticulin, a known innate immunity receptor, which has been previously proposed as a culprit in autoimmunity, plays a critical role in shared epitope-triggered signal transduction. (PMID:17947714)
• Calreticulin stimulates the anti-oxidant pathway and contributes to short-term hypoxia-induced protection in A549 type II alveolar epithelial cells. (PMID:17959730)
• Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan (PMID:17982021)
• These findings suggest that Ro52 plays a significant role in quality control of IgG1 through the endoplasmic reticulum associated degradation system. (PMID:18022694)
• Data show that the potential MBL co-receptor calreticulin binds to MBL at the MASP binding site and the interaction may involve a conformational change in MBL. (PMID:18177377)
• interaction of calreticulin with amyloid beta (Abeta) was investigated; calreticulin bound Abeta 1-42 in a time and concentration dependent fashion (PMID:18221019)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	calr	ENSDARG00000076290
mus_musculus	Calr	ENSMUSG00000003814
rattus_norvegicus	Calr	ENSRNOG00000003029
caenorhabditis_elegans		WBGENE00000802

Paralogs (3): CANX (ENSG00000127022), CLGN (ENSG00000153132), CALR3 (ENSG00000269058)

Protein

Protein identifiers

Calreticulin — P27797 (reviewed: P27797)

Alternative names: CRP55, Calregulin, Endoplasmic reticulum resident protein 60, HACBP, grp60

All UniProt accessions (6): A0A7P0T861, K7EJB9, K7EL50, K7ELE2, P27797, V9HW88

UniProt curated annotations — full annotation on UniProt →

Function. Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export. Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation of calcium homeostasis. Present in the cortical granules of non-activated oocytes, is exocytosed during the cortical reaction in response to oocyte activation and might participate in the block to polyspermy.

Subunit / interactions. Monomer. Component of an EIF2 complex at least composed of CELF1/CUGBP1, CALR, CALR3, EIF2S1, EIF2S2, HSP90B1 and HSPA5. Interacts with PDIA3/ERp57 and SPACA9. Interacts with TRIM21. Interacts with NR3C1. Interacts with PPIB. Interacts (via P-domain) with PDIA5. Interacts with GABARAP. Interacts with HLA-E-B2M and HLA-G-B2M complexes. Interacts with HLA-F. Interacts with CLCC1.

Subcellular location. Endoplasmic reticulum lumen. Cytoplasm. Cytosol. Secreted. Extracellular space. Extracellular matrix. Cell surface. Sarcoplasmic reticulum lumen. Cytoplasmic vesicle. Secretory vesicle. Cortical granule. Cytolytic granule.

Disease relevance. CALR somatic mutations are frequently found in myeloproliferative neoplasms lacking JAK2 or MPL mutations. Myeloproliferative neoplasms are chronic myeloid cancers characterized by overproduction of mature blood cells, and may evolve into acute myeloid leukemia. In addition to chronic myeloid leukemia with the BCR-ABL fusion gene, the three most common myeloproliferative neoplasms are essential thrombocythemia, polycythemia vera, and myelofibrosis.

Domain organisation. Can be divided into a N-terminal globular domain, a proline-rich P-domain forming an elongated arm-like structure and a C-terminal acidic domain. The P-domain binds one molecule of calcium with high affinity, whereas the acidic C-domain binds multiple calcium ions with low affinity. The interaction with glycans occurs through a binding site in the globular lectin domain. The zinc binding sites are localized to the N-domain. Associates with PDIA3 through the tip of the extended arm formed by the P-domain.

Similarity. Belongs to the calreticulin family.

RefSeq proteins (1): NP_004334* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001580	Calret/calnex	Family
IPR009033	Calreticulin/calnexin_P_dom_sf	Homologous_superfamily
IPR009169	Calreticulin	Family
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR018124	Calret/calnex_CS	Conserved_site

Pfam: PF00262

UniProt features (63 total): strand 18, binding site 9, region of interest 8, repeat 7, helix 5, compositionally biased region 4, modified residue 4, turn 3, signal peptide 1, chain 1, short sequence motif 1, glycosylation site 1, disulfide bond 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
3POW	X-RAY DIFFRACTION	1.55
3POS	X-RAY DIFFRACTION	1.65
2CLR	X-RAY DIFFRACTION	2
3DOW	X-RAY DIFFRACTION	2.3
5LK5	X-RAY DIFFRACTION	2.3
8TZO	ELECTRON MICROSCOPY	3.1
5V90	X-RAY DIFFRACTION	3.25
8TZR	ELECTRON MICROSCOPY	3.5
7QPD	ELECTRON MICROSCOPY	3.73
6ENY	ELECTRON MICROSCOPY	5.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P27797-F1	89.31	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (9): 26; 62; 64; 109; 111; 128; 135; 317; 328

Post-translational modifications (4): 48, 64, 159, 209

Disulfide bonds (1): 105–137

Glycosylation sites (1): 344

Function

Pathways and Gene Ontology

Reactome pathways

27 pathways

ID	Pathway
R-HSA-1236974	ER-Phagosome pathway
R-HSA-168316	Assembly of Viral Components at the Budding Site
R-HSA-3000480	Scavenging by Class A Receptors
R-HSA-3000484	Scavenging by Class F Receptors
R-HSA-381183	ATF6 (ATF6-alpha) activates chaperone genes
R-HSA-901042	Calnexin/calreticulin cycle
R-HSA-983170	Antigen Presentation: Folding, assembly and peptide loading of class I MHC
R-HSA-9918432	Maturation of DENV proteins
R-HSA-1236975	Antigen processing-Cross presentation
R-HSA-1280218	Adaptive Immune System
R-HSA-1643685	Disease
R-HSA-168255	Influenza Infection
R-HSA-168256	Immune System
R-HSA-168268	Virus Assembly and Release
R-HSA-2173782	Binding and Uptake of Ligands by Scavenger Receptors
R-HSA-2262752	Cellular responses to stress
R-HSA-381033	ATF6 (ATF6-alpha) activates chaperones
R-HSA-381119	Unfolded Protein Response (UPR)
R-HSA-392499	Metabolism of proteins
R-HSA-446203	Asparagine N-linked glycosylation
R-HSA-532668	N-glycan trimming in the ER and Calnexin/Calreticulin cycle
R-HSA-5653656	Vesicle-mediated transport
R-HSA-5663205	Infectious disease
R-HSA-597592	Post-translational protein modification
R-HSA-8953897	Cellular responses to stimuli
R-HSA-9824446	Viral Infection Pathways
R-HSA-983169	Class I MHC mediated antigen processing & presentation

MSigDB gene sets: 659 (showing top): GOBP_NEGATIVE_REGULATION_OF_REPRODUCTIVE_PROCESS, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, HONMA_DOCETAXEL_RESISTANCE, REACTOME_UNFOLDED_PROTEIN_RESPONSE_UPR, WANG_CLIM2_TARGETS_UP, GOBP_CELLULAR_RESPONSE_TO_VIRUS, GOBP_NEGATIVE_REGULATION_OF_NEURON_DIFFERENTIATION, GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_ENDOCYTOSIS, GOBP_DENDRITIC_CELL_MIGRATION, GOBP_RESPONSE_TO_ELECTRICAL_STIMULUS, GOBP_RESPONSE_TO_ESTRADIOL, GOBP_CELL_CHEMOTAXIS, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT

GO Biological Process (42): negative regulation of transcription by RNA polymerase II (GO:0000122), peptide antigen assembly with MHC class I protein complex (GO:0002502), regulation of DNA-templated transcription (GO:0006355), protein folding (GO:0006457), protein export from nucleus (GO:0006611), intracellular calcium ion homeostasis (GO:0006874), spermatogenesis (GO:0007283), positive regulation of cell population proliferation (GO:0008284), response to xenobiotic stimulus (GO:0009410), positive regulation of endothelial cell migration (GO:0010595), positive regulation of gene expression (GO:0010628), negative regulation of translation (GO:0017148), cortical actin cytoskeleton organization (GO:0030866), response to estradiol (GO:0032355), negative regulation of intracellular steroid hormone receptor signaling pathway (GO:0033144), response to testosterone (GO:0033574), protein localization to nucleus (GO:0034504), protein folding in endoplasmic reticulum (GO:0034975), ERAD pathway (GO:0036503), regulation of meiotic nuclear division (GO:0040020), nuclear receptor-mediated glucocorticoid signaling pathway (GO:0042921), regulation of apoptotic process (GO:0042981), negative regulation of neuron differentiation (GO:0045665), positive regulation of cell cycle (GO:0045787), negative regulation of DNA-templated transcription (GO:0045892), negative regulation of retinoic acid receptor signaling pathway (GO:0048387), positive regulation of phagocytosis (GO:0050766), protein stabilization (GO:0050821), obsolete sequestering of calcium ion (GO:0051208), protein maturation (GO:0051604), cardiac muscle cell differentiation (GO:0055007), cellular response to electrical stimulus (GO:0071257), cellular response to lithium ion (GO:0071285), cellular senescence (GO:0090398), cellular response to virus (GO:0098586), positive regulation of substrate adhesion-dependent cell spreading (GO:1900026), negative regulation of trophoblast cell migration (GO:1901164), positive regulation of non-canonical NF-kappaB signal transduction (GO:1901224), response to peptide (GO:1901652), response to glycoside (GO:1903416)

GO Molecular Function (20): complement component C1q complex binding (GO:0001849), DNA binding (GO:0003677), RNA binding (GO:0003723), mRNA binding (GO:0003729), nuclear export signal receptor activity (GO:0005049), integrin binding (GO:0005178), iron ion binding (GO:0005506), calcium ion binding (GO:0005509), zinc ion binding (GO:0008270), carbohydrate binding (GO:0030246), ubiquitin protein ligase binding (GO:0031625), peptide binding (GO:0042277), hormone binding (GO:0042562), protein folding chaperone (GO:0044183), nuclear androgen receptor binding (GO:0050681), obsolete unfolded protein binding (GO:0051082), protein-folding chaperone binding (GO:0051087), molecular sequestering activity (GO:0140313), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (36): acrosomal vesicle (GO:0001669), extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), nucleus (GO:0005634), nuclear envelope (GO:0005635), cytoplasm (GO:0005737), mitochondrion (GO:0005739), endoplasmic reticulum (GO:0005783), endoplasmic reticulum lumen (GO:0005788), endoplasmic reticulum membrane (GO:0005789), smooth endoplasmic reticulum (GO:0005790), cytosol (GO:0005829), ribosome (GO:0005840), focal adhesion (GO:0005925), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), membrane (GO:0016020), phagocytic vesicle membrane (GO:0030670), extracellular matrix (GO:0031012), sarcoplasmic reticulum lumen (GO:0033018), endoplasmic reticulum-Golgi intermediate compartment membrane (GO:0033116), MHC class I peptide loading complex (GO:0042824), cytolytic granule (GO:0044194), endoplasmic reticulum quality control compartment (GO:0044322), perinuclear region of cytoplasm (GO:0048471), cortical granule (GO:0060473), extracellular exosome (GO:0070062), endocytic vesicle lumen (GO:0071682), lumenal side of endoplasmic reticulum membrane (GO:0098553), postsynapse (GO:0098794), glutamatergic synapse (GO:0098978), lysosome (GO:0005764), endomembrane system (GO:0012505), sarcoplasmic reticulum (GO:0016529), cytoplasmic vesicle (GO:0031410), protein-containing complex (GO:0032991)

Reactome top-level categories

Rollup of top-15 pathways:

Category	Pathways
Binding and Uptake of Ligands by Scavenger Receptors	2
Class I MHC mediated antigen processing & presentation	2
Antigen processing-Cross presentation	1
Virus Assembly and Release	1
ATF6 (ATF6-alpha) activates chaperones	1
N-glycan trimming in the ER and Calnexin/Calreticulin cycle	1
Dengue Virus Genome Translation and Replication	1
Immune System	1
Viral Infection Pathways	1
Influenza Infection	1
Vesicle-mediated transport	1
Cellular responses to stimuli	1
Unfolded Protein Response (UPR)	1
Cellular responses to stress	1
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
binding	4
intracellular membrane-bounded organelle	3
cytoplasm	3
regulation of gene expression	2
nuclear export	2
response to chemical	2
response to lipid	2
protein folding	2
protein-containing complex binding	2
nucleic acid binding	2
transition metal ion binding	2
molecular_function	2
endomembrane system	2
endoplasmic reticulum	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
MHC class I protein complex assembly	1
antigen processing and presentation of peptide antigen via MHC class I	1
peptide antigen assembly with MHC protein complex	1
DNA-templated transcription	1
regulation of RNA biosynthetic process	1
cellular process	1
protein maturation	1
intracellular protein transport	1
intracellular monoatomic cation homeostasis	1
calcium ion homeostasis	1
developmental process involved in reproduction	1
male gamete generation	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
regulation of endothelial cell migration	1
positive regulation of cell migration	1
endothelial cell migration	1
gene expression	1
positive regulation of macromolecule biosynthetic process	1
translation	1
regulation of translation	1

Protein interactions and networks

STRING

5180 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CALR	PDIA3	P30101	999
CALR	LRP1	Q07954	998
CALR	TAPBP	O15533	998
CALR	B2M	P01884	990
CALR	CANX	P27824	988
CALR	THBS1	P07996	988
CALR	HSP90B1	P14625	976
CALR	MBL2	P11226	974
CALR	PPIB	P23284	962
CALR	NUCLEOLIN	P19338	962
CALR	HSP90AA1	P07900	958
CALR	HSP90AB1	P08238	958
CALR	HSPA5	P11021	956
CALR	TLR4	O00206	952
CALR	HSPA4	P34932	949

IntAct

458 interactions, top by confidence:

A	B	Type	Score
H2AX	PARP1	psi-mi:“MI:0914”(association)	0.840
TAP1	TAPBP	psi-mi:“MI:0914”(association)	0.800
TCTN2	CLGN	psi-mi:“MI:0914”(association)	0.780
APP	CALR	psi-mi:“MI:0914”(association)	0.740
APP	CALR	psi-mi:“MI:0915”(physical association)	0.740
CALR	PDIA3	psi-mi:“MI:0915”(physical association)	0.670
MTNR1A	CALR	psi-mi:“MI:0915”(physical association)	0.660
INAVA	CYTH3	psi-mi:“MI:0914”(association)	0.640
B2M	TAPBP	psi-mi:“MI:0915”(physical association)	0.570
CALR	TAF1B	psi-mi:“MI:0915”(physical association)	0.560
GSC2	CALR	psi-mi:“MI:0915”(physical association)	0.560
CALR	SGTB	psi-mi:“MI:0915”(physical association)	0.560
CALR		psi-mi:“MI:0915”(physical association)	0.560
CALR	DNASE1L1	psi-mi:“MI:0915”(physical association)	0.560
CALR	FUT2	psi-mi:“MI:0915”(physical association)	0.560
CALR	GJA5	psi-mi:“MI:0915”(physical association)	0.560
CALR	GNAO1	psi-mi:“MI:0915”(physical association)	0.560
CALR	HLA-DRB3	psi-mi:“MI:0915”(physical association)	0.560
CALR	HSD3B1	psi-mi:“MI:0915”(physical association)	0.560
CALR	IDH1	psi-mi:“MI:0915”(physical association)	0.560
CALR	KLRC1	psi-mi:“MI:0915”(physical association)	0.560
CALR	LGALS1	psi-mi:“MI:0915”(physical association)	0.560
CALR	LGALS8	psi-mi:“MI:0915”(physical association)	0.560
CALR	EPCAM	psi-mi:“MI:0915”(physical association)	0.560
CALR	MAGEA2	psi-mi:“MI:0915”(physical association)	0.560
CALR	CNOT3	psi-mi:“MI:0915”(physical association)	0.560
CALR	PPEF1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (547): CALR (Affinity Capture-MS), CALR (Affinity Capture-MS), CALR (Affinity Capture-MS), CALR (Affinity Capture-MS), CALR (Affinity Capture-MS), CALR (Affinity Capture-MS), CALR (Affinity Capture-MS), CALR (Two-hybrid), CALR (Affinity Capture-Western), CALR (Co-fractionation), CALR (Co-fractionation), CALR (Co-fractionation), CALR (Co-fractionation), CALR (Co-fractionation), CALR (Co-fractionation)

ESM2 similar proteins: A0A0D1C6P2, A8XA40, D4AVD4, E2RA18, J9VLH0, O04151, O04153, O14967, O81919, O82709, P11012, P14211, P18418, P24643, P27797, P27798, P27824, P28491, P29402, P29413, P34652, P35564, P35565, P36581, P52193, P52194, P83003, P93508, Q06814, Q23858, Q2HWU3, Q2TBR8, Q38798, Q38858, Q39817, Q39994, Q3SYT6, Q40401, Q4R6K8, Q4VIT5

Diamond homologs: A0A0D1C6P2, A8XA40, D4AVD4, E2RA18, J9VLH0, O04151, O04153, O14967, O81919, O82709, P11012, P14211, P15253, P18418, P24643, P27797, P27798, P27824, P27825, P28491, P29402, P29413, P34652, P35564, P35565, P36581, P52193, P52194, P83003, P93508, Q06814, Q23858, Q2HWU3, Q2TBR8, Q38798, Q38858, Q39817, Q39994, Q3SYT6, Q40401

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 160 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Antigen Presentation: Folding, assembly and peptide loading of class I MHC	6	21.3×	2e-04
ER-Phagosome pathway	8	9.3×	7e-04

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

96 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	43
Likely benign	11
Benign	14

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1028735	NM_004343.4(CALR):c.1154_1155insTTGTC (p.Lys385fs)	Pathogenic

SpliceAI

928 predictions. Top by Δscore:

Variant	Effect	Δscore
19:12938768:G:GT	donor_gain	1.0000
19:12939130:TTAG:T	acceptor_loss	1.0000
19:12939131:TAGAC:T	acceptor_loss	1.0000
19:12939132:A:AG	acceptor_gain	1.0000
19:12939132:AGAC:A	acceptor_gain	1.0000
19:12939132:AGACG:A	acceptor_gain	1.0000
19:12939133:G:GG	acceptor_gain	1.0000
19:12939133:G:GT	acceptor_loss	1.0000
19:12939133:GAC:G	acceptor_gain	1.0000
19:12939133:GACG:G	acceptor_gain	1.0000
19:12939133:GACGG:G	acceptor_gain	1.0000
19:12939426:AG:A	acceptor_gain	1.0000
19:12939427:GG:G	acceptor_gain	1.0000
19:12939427:GGT:G	acceptor_gain	1.0000
19:12939627:GTTTG:G	donor_gain	1.0000
19:12939630:TGGTG:T	donor_loss	1.0000
19:12939631:GGTG:G	donor_loss	1.0000
19:12939632:G:GA	donor_loss	1.0000
19:12939632:G:GG	donor_gain	1.0000
19:12939633:T:A	donor_loss	1.0000
19:12940046:C:G	acceptor_gain	1.0000
19:12940048:C:G	acceptor_gain	1.0000
19:12940048:CCTA:C	acceptor_loss	1.0000
19:12940049:CTAGG:C	acceptor_loss	1.0000
19:12940050:TAG:T	acceptor_loss	1.0000
19:12940051:A:AC	acceptor_loss	1.0000
19:12940051:A:AG	acceptor_gain	1.0000
19:12940052:G:GG	acceptor_gain	1.0000
19:12940133:GACA:G	donor_gain	1.0000
19:12940144:CAAGG:C	donor_loss	1.0000

AlphaMissense

2830 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:12939454:T:C	F74L	1.000
19:12939456:T:A	F74L	1.000
19:12939456:T:G	F74L	1.000
19:12939547:T:A	C105S	1.000
19:12939547:T:C	C105R	1.000
19:12939548:G:A	C105Y	1.000
19:12939548:G:C	C105S	1.000
19:12939548:G:T	C105F	1.000
19:12939549:T:G	C105W	1.000
19:12939551:G:A	G106E	1.000
19:12939565:A:G	K111E	1.000
19:12939567:G:C	K111N	1.000
19:12939567:G:T	K111N	1.000
19:12939631:G:C	G133R	1.000
19:12940053:G:A	G133D	1.000
19:12940058:G:C	D135H	1.000
19:12940059:A:T	D135V	1.000
19:12940064:T:A	C137S	1.000
19:12940064:T:C	C137R	1.000
19:12940065:G:A	C137Y	1.000
19:12940065:G:C	C137S	1.000
19:12940065:G:T	C137F	1.000
19:12940066:T:G	C137W	1.000
19:12940088:C:G	H145D	1.000
19:12940271:T:C	L174P	1.000
19:12940595:T:A	W253R	1.000
19:12940595:T:C	W253R	1.000
19:12940597:G:C	W253C	1.000
19:12940597:G:T	W253C	1.000
19:12940619:T:A	W261R	1.000

dbSNP variants (sampled 300 via entrez): RS1000233859 (19:12938498 AC>A), RS1000416138 (19:12941902 C>T), RS1000468582 (19:12942199 T>C), RS1000629156 (19:12942229 G>C,T), RS1000646103 (19:12936789 G>A), RS1000842095 (19:12937756 C>T), RS1000890928 (19:12942319 T>G), RS1001540161 (19:12937962 G>C), RS1001584139 (19:12942873 C>T), RS1001915386 (19:12938004 G>A), RS1002033044 (19:12942870 C>T), RS1002085136 (19:12943044 G>A), RS1002142483 (19:12943285 C>G,T), RS1002182121 (19:12941936 A>G), RS1002333831 (19:12937466 G>A)

Disease associations

OMIM: gene MIM:109091 | disease phenotypes: MIM:187950, MIM:254450

GenCC curated gene-disease

Mondo (2): thrombocythemia 1 (MONDO:0008554), primary myelofibrosis (MONDO:0009692)

Orphanet (1): Primary myelofibrosis (Orphanet:824)

HPO phenotypes

84 total (30 of 84 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000083	Renal insufficiency
HP:0000505	Visual impairment
HP:0000952	Jaundice
HP:0000967	Petechiae
HP:0000978	Bruising susceptibility
HP:0000979	Purpura
HP:0000980	Pallor
HP:0001028	Hemangioma
HP:0001082	Cholecystitis
HP:0001394	Cirrhosis
HP:0001409	Portal hypertension
HP:0001433	Hepatosplenomegaly
HP:0001442	Typified by somatic mosaicism
HP:0001541	Ascites
HP:0001658	Myocardial infarction
HP:0001744	Splenomegaly
HP:0001824	Weight loss
HP:0001871	Abnormality of blood and blood-forming tissues
HP:0001872	Abnormality of thrombocytes
HP:0001873	Thrombocytopenia
HP:0001876	Pancytopenia
HP:0001892	Abnormal bleeding
HP:0001894	Thrombocytosis
HP:0001903	Anemia
HP:0001945	Fever
HP:0001974	Increased total leukocyte count
HP:0001977	Abnormal thrombosis
HP:0001978	Extramedullary hematopoiesis
HP:0002024	Malabsorption

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001765_24	Red blood cell traits	8.000000e-20
GCST002595_9	Clozapine-induced agranulocytosis	1.000000e-06
GCST008058_230	Estimated glomerular filtration rate	7.000000e-12
GCST90002402_616	Platelet count	9.000000e-10

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin
EFO:0004309	platelet count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D055728	Primary Myelofibrosis	C15.378.190.636.765

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066425 (SINGLE PROTEIN)

Clinical evidence (CIViC)

Drug × variant × indication: 1 predictive associations from 1 curated evidence items; also 6 prognostic, 1 diagnostic.

Variant	Therapy	Indication	Effect	Level	CIViC
CALR EXON 9 FRAMESHIFT	Peginterferon Alfa-2a	Essential Thrombocythemia	Sensitivity/Response	CIViC B	EID1482

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

119 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tunicamycin	increases expression	6
bisphenol A	affects expression, affects cotreatment, decreases methylation, decreases expression, increases expression	5
sodium arsenite	decreases expression, increases abundance, increases expression	5
Cadmium Chloride	decreases reaction, increases abundance, increases palmitoylation, increases expression	4
Thapsigargin	increases expression	4
Resveratrol	affects secretion, decreases reaction, increases expression, decreases expression	3
Doxorubicin	affects expression, affects cotreatment, affects localization, increases expression, increases reaction (+1 more)	3
Tobacco Smoke Pollution	affects expression, increases expression	3
cobaltous chloride	decreases expression	2
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	2
7,8-diacetoxy-4-methylcoumarin	increases activity, increases acetylation, increases reaction	2
Arsenic Trioxide	decreases expression, increases expression, decreases reaction	2
Acrolein	affects cotreatment, increases oxidation, increases abundance	2
Air Pollutants	increases abundance, increases oxidation, increases expression, affects cotreatment	2
Cadmium	decreases reaction, increases abundance, increases palmitoylation, increases expression	2
Nickel	increases expression	2
Ozone	affects cotreatment, increases oxidation, increases abundance	2
Rotenone	decreases expression, increases expression	2
Valproic Acid	decreases expression, increases expression, affects reaction	2
Aflatoxin B1	increases methylation	2
Okadaic Acid	increases expression	2
Particulate Matter	increases expression, affects expression, increases abundance	2
bisphenol F	increases expression	1
beta-N-methylamino-L-alanine	increases expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
chlorophyllin	decreases expression	1
potassium perchlorate	decreases expression	1
sodium arsenate	decreases expression	1
titanium dioxide	increases phosphorylation	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651023	Binding	Binding affinity to human CALR incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

9 cell lines: 7 cancer cell line, 2 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_6992	Marimo	Cancer cell line	Female
CVCL_B8CC	Abcam HCT 116 CALR KO	Cancer cell line	Male
CVCL_B8T8	Abcam MCF-7 CALR KO	Cancer cell line	Female
CVCL_B9EI	Abcam A-549 CALR KO	Cancer cell line	Male
CVCL_LK61	INCABRi001-A	Induced pluripotent stem cell	Female
CVCL_SG61	HAP1 CALR (-) 1	Cancer cell line	Male
CVCL_SG62	HAP1 CALR (-) 2	Cancer cell line	Male
CVCL_SG63	HAP1 CALR (-) 3	Cancer cell line	Male
CVCL_VD83	INCABRi002-A	Induced pluripotent stem cell	Male

Clinical trials (associated diseases)

173 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01558739	PHASE4	COMPLETED	Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
NCT02386800	PHASE4	ACTIVE_NOT_RECRUITING	CINC424A2X01B Rollover Protocol
NCT00799461	PHASE3	COMPLETED	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
NCT01178281	PHASE3	COMPLETED	Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
NCT01387763	PHASE3	COMPLETED	A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
NCT01773187	PHASE3	TERMINATED	Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
NCT01969838	PHASE3	COMPLETED	Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
NCT02055781	PHASE3	TERMINATED	Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
NCT02087059	PHASE3	COMPLETED	A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
NCT02101268	PHASE3	COMPLETED	Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
NCT03165734	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03755518	PHASE3	TERMINATED	A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
NCT03952039	PHASE3	COMPLETED	An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
NCT04173494	PHASE3	COMPLETED	A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
NCT04551053	PHASE3	TERMINATED	To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
NCT04551066	PHASE3	TERMINATED	To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04603495	PHASE3	ACTIVE_NOT_RECRUITING	Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04717414	PHASE3	ACTIVE_NOT_RECRUITING	An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT06351631	PHASE3	RECRUITING	A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
NCT06468033	PHASE3	RECRUITING	P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06479135	PHASE3	RECRUITING	Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT07357727	PHASE3	RECRUITING	A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT00015821	PHASE2	COMPLETED	Thalidomide in Treating Patients With Myelofibrosis
NCT00039416	PHASE2	COMPLETED	Imatinib Mesylate in Treating Patients With Myelofibrosis
NCT00047190	PHASE2	COMPLETED	Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
NCT00086125	PHASE2	COMPLETED	Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
NCT00089011	PHASE2	COMPLETED	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
NCT00095784	PHASE2	ACTIVE_NOT_RECRUITING	Decitabine in Treating Patients With Myelofibrosis
NCT00136409	PHASE2	COMPLETED	A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
NCT00227591	PHASE2	COMPLETED	Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
NCT00255346	PHASE2	COMPLETED	Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
NCT00287261	PHASE2	COMPLETED	A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)
NCT00381550	PHASE2	COMPLETED	3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
NCT00387426	PHASE2	TERMINATED	Sunitinib in Treating Patients With Idiopathic Myelofibrosis
NCT00397813	PHASE2	COMPLETED	Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
NCT00463385	PHASE2	COMPLETED	A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
NCT00489203	PHASE2	COMPLETED	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
NCT00570999	PHASE2	WITHDRAWN	Palifermin After Haploidentical PBSCT
NCT00795769	PHASE2	COMPLETED	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
NCT00931762	PHASE2	TERMINATED	A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis